



SCOHIA PHARMA, Inc.

May 28, 2021

SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)

SCOHIA PHARMA, Inc., announced today that an SSTR5 antagonist (SCO-240) has progressed to a phase 1 study in healthy adult volunteers.

This is a randomized, placebo-controlled, double-blind, single-center study conducted to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of a single oral dose of SCO-240.

For more information about the study, please visit the following website:

<https://jrct.niph.go.jp/search> (please search using jRCT2051210027)

[About SSTR5 antagonist, SCO-240]

Somatostatin is a peptide hormone secreted from the pituitary gland, pancreas, and gastrointestinal endocrine cells, and regulates secretion of endocrine hormones via five G-protein-coupled receptors (SSTR1-5). SCO-240, identified by SCOHIA researchers and collaborators, is an orally available, selective SSTR5 antagonist, and is unique owing to its action on various hormone secretions. SCO-240 has a potential application in the treatment of type2 diabetes, cholelithiasis and primary sclerosing cholangitis.

[About SCOHIA PHARMA, Inc.]

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit <https://www.scohia.com/eng/>.

Contact for inquiries: info@scohia.com